Search research articles
Contact Us
Filters
Showing results (561-570 of 651) with videos related to
Page
of 66
Sort By:
American Journal of Hematology
|
November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries
Christian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
EMBO Molecular Medicine
|
March 7, 2022
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
Lixiazi He, Christian Arnold, Judith Thoma, et al.
Nature Cell Biology
|
February 21, 2024
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
Tobias Roider, Marc A Baertsch, Donnacha Fitzgerald, et al.
Leukemia
|
December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma
Martin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Leukemia
|
November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Christian Récher, Christoph Röllig, Emilie Bérard, et al.
Trials
|
September 15, 2023
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, et al.
Blood Cancer Journal
|
July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
Emilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Blood Cancer Discovery
|
February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Jan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Nature Cell Biology
|
June 17, 2020
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels
Tobias Roider, Julian Seufert, Alexey Uvarovskii, et al.
Cancer Cell
|
April 12, 2017
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia
Sebastian Mohr, Carmen Doebele, Federico Comoglio, et al.
Page
of 66
Search research articles
Search
Showing results (561-570 of 651) with videos related to
Sort By:
Page
of 66
American Journal of Hematology
|
November 18, 2024
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries
Christian Récher, Pierre-Yves Dumas, Emilie Bérard, et al.
EMBO Molecular Medicine
|
March 7, 2022
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
Lixiazi He, Christian Arnold, Judith Thoma, et al.
Nature Cell Biology
|
February 21, 2024
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities
Tobias Roider, Marc A Baertsch, Donnacha Fitzgerald, et al.
Leukemia
|
December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma
Martin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Leukemia
|
November 14, 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Christian Récher, Christoph Röllig, Emilie Bérard, et al.
Trials
|
September 15, 2023
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
Sonia Jaramillo, Lucian Le Cornet, Markus Kratzmann, et al.
Blood Cancer Journal
|
July 12, 2022
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
Emilie Bérard, Christoph Röllig, Sarah Bertoli, et al.
Blood Cancer Discovery
|
February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapy
Jan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Nature Cell Biology
|
June 17, 2020
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels
Tobias Roider, Julian Seufert, Alexey Uvarovskii, et al.
Cancer Cell
|
April 12, 2017
Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia
Sebastian Mohr, Carmen Doebele, Federico Comoglio, et al.
Page
of 66